Platinum Priority – Prostate CancerEditorial by Peter C. Albertsen on pp. 9–11 of this issueOutcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly☆
Introduction
The incidence of prostate cancer (PCa) has been rising during the last 2 decades [1]. Prostate-specific antigen (PSA)–driven screening is probably the most important underlying reason for this trend [2]. In addition to other effects, present screening leads to a more frequent detection of small, localised, well-differentiated malignancies [3], [4].
With death resulting from other causes often occurring before these tumours become harmful, radical treatment may have no effect on PCa-specific survival in these patients [5]. At present, most of these early cancers are radically treated, carrying a chance of serious side-effects [6], [7], [8].
Active surveillance (AS) is an emerging treatment strategy aimed at avoiding overtreatment in patients with PCa. AS consists of initially following men with early PCa and starting curative surgery or radiation therapy (RT), only when progression occurs. AS delays treatment in some men and in others allows treatment to be avoided completely in others [9], [10]. The criteria for inclusion and for switching towards active therapy are not yet evidence based [11].
The present multicenter study aims to validate the currently used criteria for eligibility for AS, by retrospectively studying outcome measures in men with screen-detected PCa that fits these criteria and who were managed expectantly.
Section snippets
Methods
Men included in this study all participated in the screening arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC), had been diagnosed with PCa, and initially had elected expectant management. The data cohorts of four centres in three countries were combined, that is, Rotterdam in the Netherlands, Gothenburg in Sweden, and Helsinki and Tampere in Finland.
The ERSPC-screening protocol (applied to men aged 50–75 yr) consists of PSA measurements (threshold 3.0 or 4.0 ng/ml),
Results
In total, 988 men were primarily managed expectantly after PCa diagnosis; of those, 616 (62.3%) conformed to the PRIAS criteria for AS. Of the 372 (988 – 616) excluded men, 49 had a PSA level >10.0 ng/ml (12 unknown), 130 had a PSA density ≥0.2 ng/ml per ml (89 unknown), 4 had disease stage >T2 (24 unknown), 54 had Gleason score >3 + 3 = 6 (24 unknown), and 108 had more than two positive biopsy cores (93 unknown). One man had positive lymph nodes at the time of diagnosis, and one had distant
Discussion
We retrospectively studied PCa-specific-, overall-, and treatment-free survival of men with screen-detected PCa that was initially managed expectantly and who would have been suitable for AS according to contemporary practice. In the first screening round of the Rotterdam section of the ERSPC, 21.8% of all men who were possibly suitable for AS were actually treated expectantly [19].
Differences between the four centres in patient selection and follow-up were small but significant. These can be
Conclusions
This retrospective ERSPC multicenter study confirms that expectant management is a part of the clinical management of screen-detected PCa. The border between AS and WW is not distinct. Men with screen-detected PCa that fits current criteria for AS have a favourable PCa-specific prognosis, after initially choosing an expectant management; after 10 yr of follow-up, 100% survived their PCa, whereas almost one-fourth had died of other causes. On the basis of present PSA characteristics, it is also
References (28)
- et al.
The epidemiology of prostate cancer
Urol Clin North Am
(2003) - et al.
Screening for prostate cancer: an update
Eur Urol
(2008) - et al.
The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study
J Urol
(1999) - et al.
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics
Eur Urol
(2008) - et al.
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE
J Urol
(2003) - et al.
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study
J Urol
(2008) Active surveillance: towards a new paradigm in the management of early prostate cancer
Lancet Oncol
(2004)- et al.
Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome
Eur Urol
(2007) Watching the face of Janus – active surveillance as a strategy to reduce overtreatment for localised prostate cancer
Eur Urol
(2006)- et al.
Prospective validation of active surveillance in prostate cancer: the PRIAS study
Eur Urol
(2007)
Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression
J Urol
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen
Urology
Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis
J Urol
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance
Eur Urol
Cited by (226)
Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance
2023, Urologic Oncology: Seminars and Original InvestigationsComparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy
2018, Clinical Genitourinary Cancer
- ☆
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.